F8IL10 + methotrexate

**F8IL10 + methotrexate** is a combination therapy designed for the treatment of active rheumatoid arthritis. F8IL10 (also called Dekavil) is a fusion protein consisting of the F8 single-chain antibody fragment, which targets the extra-domain-A (ED-A) of fibronectin expressed at sites of inflammation, fused to the anti-inflammatory cytokine interleukin-10 (IL10). This construction enables localized delivery of IL10 to inflamed synovial tissue, enhancing anti-inflammatory effects while minimizing systemic exposure. Methotrexate is a standard disease-modifying antirheumatic drug which inhibits dihydrofolate reductase, suppressing immune system overactivity. The combination aims to improve efficacy in rheumatoid arthritis by adding targeted cytokine therapy to conventional immunosuppressive treatment[2][3][1]. Clinical studies have evaluated safety, pharmacokinetics, immunogenicity, and anti-rheumatic activity, focusing on dose escalation and recommended dose finding for the combination[1][2][3].

Brand names

Dekavil + methotrexate

Other names

F8IL10F-8IL10F 8IL10F8-IL10F-8-IL10F 8-IL10IL10-F8 fusionIL-10-F8 fusionIL 10-F8 fusionDekavil + methotrexate